GlassScriptPhysician profile
Rachel Maynard
NPI 1093467052
$3,771.14
in general payments reported to CMS, 2019-2025
15 companies · $951 in 2025
The $951 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,064 · 2023: $734 · 2024: $1,022 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.99 |
| Education | $256.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $610.06 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $480.11 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $474.92 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $453.18 | 2022-2025 | Caplyta |
| Alkermes, INC. | $440.70 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $314.46 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $259.73 | 2024-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $179.23 | 2022-2024 | Qelbree |
| Lundbeck LLC | $164.36 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $149.55 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $66.58 | 2023-2025 | Auvelity |
| Indivior INC. | $56.02 | 2022-2024 | Sublocade, Perseris |
| Uswm, LLC | $52.68 | 2023 | Zimhi, Lucemyra |
| E.R. Squibb & Sons, L.L.C. | $38.34 | 2024-2025 | Cobenfy |
| Braeburn INC. | $31.22 | 2023-2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.